Skip to main content

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Trial Status: Active

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Inclusion Criteria

  • Classic Hodgkin Lymphoma (cHL), relapsed or refractory
  • Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
  • One prior anti-cancer therapy that did not work

Exclusion Criteria

  • Active, known, or suspected autoimmune disease or infection
  • Active cerebral/meningeal disease related to the underlying malignancy
  • More than one line of anti-cancer therapy or no treatment at all
  • Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
  • Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

California

Palo Alto
Stanford Cancer Institute Palo Alto
Status: ACTIVE

Colorado

Aurora
Children's Hospital Colorado
Status: ACTIVE

Connecticut

New Haven
Yale University
Status: ACTIVE

Georgia

Atlanta
Children's Healthcare of Atlanta - Egleston
Status: APPROVED

Indiana

Indianapolis
Indiana University / Melvin and Bren Simon Cancer Center
Status: ACTIVE
Contact: Melissa Lee
Phone: 317-944-4281
Email: mellee@iu.edu
Riley Hospital for Children
Status: CLOSED_TO_ACCRUAL
Contact: Melissa Lee
Phone: 317-944-4281
Email: mellee@iu.edu

Iowa

Iowa City
University of Iowa / Holden Comprehensive Cancer Center
Status: ACTIVE

Kansas

Kansas City
University of Kansas Cancer Center
Status: ACTIVE

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE

Massachusetts

Boston
Boston Children's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE

Michigan

Detroit
Wayne State University / Karmanos Cancer Institute
Status: APPROVED

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE

New Jersey

New Brunswick
Rutgers Cancer Institute of New Jersey
Status: ACTIVE

New York

Buffalo
Roswell Park Cancer Institute
Status: ACTIVE

North Carolina

Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Status: ADMINISTRATIVELY_COMPLETE

Ohio

Columbus
Nationwide Children's Hospital
Status: ACTIVE

Pennsylvania

Philadelphia
Children's Hospital of Philadelphia
Status: ACTIVE
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE

Texas

Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Houston
Texas Children's Hospital
Status: ACTIVE

Utah

Salt Lake City
Primary Children's Hospital
Status: ACTIVE

Virginia

Richmond
Virginia Commonwealth University / Massey Cancer Center
Status: ACTIVE

Washington

Seattle
Seattle Children's Hospital
Status: ACTIVE

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA209-744
  • Secondary IDs NCI-2017-01473, 2016-002347-41
  • Clinicaltrials.gov ID NCT02927769